Biotech companies are innovating with cutting-edge technologies to develop game-changing products for patients. Investing early can lead to significant wins, but also comes with risks. Choosing a more established company with products on the market can offer innovation with lower risk.

Vertex Pharmaceuticals leads the cystic fibrosis treatment market, changing lives with approved drugs since 2012. Their treatments address most cases of CF, with ongoing innovation to help more patients. New products like Casgevy and Journavx are expected to bring in at least $500 million in revenue this year.

Vertex Pharmaceuticals is positioned for long-term success with ongoing innovation in CF and new product launches. The company forecasts up to $13.1 billion in total revenue this year, with blockbuster opportunities in their non-CF products. Considered the ultimate biotech stock to buy with $500 right now.

The Motley Fool Stock Advisor team identified the 10 best stocks to buy now, but Vertex Pharmaceuticals wasn’t included. Their top stock picks have historically produced significant returns, outperforming the market. Don’t miss out on the latest list and join an investing community focused on individual investors.

Read more at Yahoo Finance: The Ultimate Biotech Stock to Buy With $500 Right Now